FDA considers curbing use of erythropoietins for patients with cancerBMJ 2007; 334 doi: https://doi.org/10.1136/bmj.334.7607.1297 (Published 21 June 2007) Cite this as: BMJ 2007;334:1297
The controversy surrounding overuse of synthetic erythropoietins in the US has shifted lately to patients with cancer, who are given these agents for the anaemia associated with chemotherapy⇑. While treatment helps patients avoid blood transfusions, the potential risks include thromboembolism (already seen in patients …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial